139 related articles for article (PubMed ID: 10810051)
1. Irritable bowel syndrome. New treatment drug on the market.
Harv Health Lett; 2000 Jun; 25(8):7. PubMed ID: 10810051
[No Abstract] [Full Text] [Related]
2. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
3. [New therapeutic approaches in irritable bowel syndrome].
Müller-Lissner SA
Z Gastroenterol; 2000 Sep; 38(9):815-6. PubMed ID: 11072681
[No Abstract] [Full Text] [Related]
4. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Avigan M; Justice R; Mackey AC; Nair N
Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
[No Abstract] [Full Text] [Related]
5. Glaxo Wellcome withdraws irritable bowel syndrome medication.
FDA Consum; 2001; 35(1):3. PubMed ID: 11930921
[No Abstract] [Full Text] [Related]
6. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
7. Alosetron: ischemic colitis and serious complications of constipation.
Gallo-Torres H; Brinker A; Avigan M
Am J Gastroenterol; 2006 May; 101(5):1080-3. PubMed ID: 16696787
[TBL] [Abstract][Full Text] [Related]
8. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
McGahan L
Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
[No Abstract] [Full Text] [Related]
9. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
10. Drug for irritable bowel syndrome taken off the market.
Charatan F
BMJ; 2000 Dec; 321(7274):1429. PubMed ID: 11228674
[No Abstract] [Full Text] [Related]
11. Novel medications for the irritable bowel syndrome: motility and sensation.
Camilleri M
J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419
[No Abstract] [Full Text] [Related]
12. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
[TBL] [Abstract][Full Text] [Related]
13. Neurotransmitter antagonism in management of irritable bowel syndrome.
Lembo T
Lancet; 2000 Mar; 355(9209):1030-1. PubMed ID: 10744083
[No Abstract] [Full Text] [Related]
14. FDA draws patients into alosetron risk management.
Miller JL
Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
[No Abstract] [Full Text] [Related]
15. Alosetron: a new therapy for irritable bowel syndrome.
Kupecz D
Nurse Pract; 2000 Jul; 25(7):95-6, 98-100. PubMed ID: 10916831
[No Abstract] [Full Text] [Related]
16. Alosetron for irritable bowel syndrome.
Barbehenn E; Lurie P; Wolfe SM
Lancet; 2000 Dec; 356(9246):2009-10. PubMed ID: 11130544
[No Abstract] [Full Text] [Related]
17. So what happened to alosetron?
Hyams JS
J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
[No Abstract] [Full Text] [Related]
18. [Soon one "female distress" less. Irritable bowel syndrome responds to serotonin blockers].
MMW Fortschr Med; 2000 Sep; 142(37):55. PubMed ID: 11026224
[No Abstract] [Full Text] [Related]
19. New drugs to treat irritable bowel syndrome being tested.
Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
[No Abstract] [Full Text] [Related]
20. Alosetron approved for treatment of irritable bowel syndrome.
Miller JL
Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758
[No Abstract] [Full Text] [Related]
[Next] [New Search]